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New findings 
• What is the central question of this study?  
The parasternal intercostal electromyogram (EMGpara) is known to provide an 
accurate, non-invasive index of respiratory load-capacity balance.  Although 
relationships between EMGpara and both airflow obstruction and hyperinflation 
have been shown, the independent contribution of each factor has not been 
examined. 
 
• What is the main finding and its importance?  
Reductions in airway calibre and inspiratory capacity (IC) along with increases in 
EMGpara were induced via methacholine challenge.  A strong inverse relationship 
was observed between EMGpara and airway obstruction with no influence of IC.  
These data suggest that EMGpara is more strongly influenced by airway calibre than 
by changes in end-expiratory lung volume during airway challenge testing. 
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Abstract 
Neural respiratory drive, measured via the parasternal intercostal electromyogram 
(EMGpara), provides a non-invasive index of the load-capacity balance of the 
respiratory muscle pump.  Previous studies in patients with obstructive lung disease 
have shown strong relationships between EMGpara and the extent of both airflow 
obstruction and hyperinflation.  The relative influence of the two factors has not, 
however, been described.  Airflow obstruction was induced via methacholine 
challenge testing in twenty-five adult humans.  Forced expiratory volume in one 
second (FEV1) and surface EMGpara during tidal breathing were measured following 
each dose, with twenty of the participants also undergoing measurements of 
inspiratory capacity (IC) at each stage.  Linear mixed model (LMM) analysis was used 
to assess dose-wise changes in FEV1 and EMGpara, and thereafter to determine the 
influence of changes in FEV1 and IC on change in EMGpara.  Median (IQR) FEV1 
decreased significantly (96.00 (80.00 – 122.30)%predicted to 67.80 (37.98 – 
92.27)%predicted, p<0.0001) and EMGpara increased significantly (5.37 (2.25 – 
8.92)µV to 6.27 (3.37 – 19.60)µV, p<0.0001) from baseline to end of test.  LMM 
analysis showed a significant interaction between methacholine dose and induced 
change in EMGpara, with an increase in EMGpara of 0.24 (95% confidence interval 
0.11 – 0.37)µV per methacholine dose2.  Change in FEV1 further influenced this 
relationship (increase in slope of 0.002 (0.004 – 0.001)µV dose-2 per %predicted fall 
in FEV1, p=0.011), but not with change in IC.  These data suggest that 
bronchoconstriction exerts a more potent influence on levels of EMGpara than 
changes in end expiratory lung volume during methacholine challenge. 
Abstract word count: 245 words  
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Abbreviations 
 
ECG, electrocardiogram;  EMGpara, parasternal intercostal electromyogram; EOT, 
end of test; FEV1, forced expiratory volume in one second; FRC, functional residual 
capacity; FVC, forced vital capacity; Hz, Hertz; IC, inspiratory capacity; IQR, 
interquartile range; kg, kiligram; L, litre; LMM, linear mixed models; mg, milligram; 
µg, migrogram; µV, microvolt; min, minute; ml, millilitre; mm, millimetre; ms, 
millisecond; NRD, neural respiratory drive; PC20, provocative concentration of 
methacholine inducing a 20% fall in FEV1; REML, restricted maximum likelihood; 
RMS, root mean square; sec, second; TLC, total lung capacity. 
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Introduction  
Measures that allow the severity of respiratory disease to be accurately quantified 
are essential for optimal patient management.  The majority of assessment 
techniques in current use examine a single component of respiratory function, such 
as airflow obstruction or lung volumes.  Measurements of neural respiratory drive 
(NRD), obtained from respiratory muscle electromyography, provides an index of the 
overall load on the respiratory system and represents a promising method for 
assessment of the severity of lung disease. 
 
The pathophysiological changes that occur in obstructive lung diseases adversely 
influence the load-capacity balance of the respiratory muscle pump.  Elevated airway 
resistance, together with distal airway collapse and gas trapping resulting in intrinsic 
positive end-expiratory pressure, all impose loads on the respiratory muscles during 
inspiration.  Additionally, increases in end-expiratory lung volume result in 
respiratory muscle shortening and mechanical disadvantage, reducing their force-
generating capacity and leading to functional weakness (Moxham & Jolley, 2009).  In 
the face of such changes in load and capacity, compensatory increases in NRD occur 
to maintain ventilation at an appropriate level for blood gas homeostasis. 
 
Studies in patients with moderate to severe lung disease have demonstrated strong 
relationships between NRD and the extent of both airflow obstruction and 
hyperinflation (Jolley et al., 2009; Reilly et al., 2011).  The relative influence of the 
two factors has not, however, been described.  Reilly et al. (2011) reported 
progressive increases in NRD, measured using both the diaphragm (EMGdi) and 
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parasternal intercostal electromyogram (EMGpara), during incremental exercise in 
patients with cystic fibrosis and matched healthy controls.  The patients 
demonstrated exercise-induced dynamic hyperinflation, but the relative influence of 
such changes in end expiratory lung volume over and above that imposed by airway 
resistance and the metabolic load of the exercise was not described. 
 
Airway challenge testing allows stepwise decrements in pulmonary function to be 
induced under controlled circumstances.  Bronchoconstriction is the primary change 
occurring during airway challenge testing, although hyperinflation may also occur in 
some individuals (American Thoracic Society, 2000).  Airway challenge testing 
provides a model by which the changes in NRD resulting from acute, stepwise 
changes in pulmonary function can be assessed, without the confounding influences 
that may be encountered in a longitudinal study in patients with lung disease such as 
the metabolic influences of infection or changes in medication. 
 
The aims of this study were, therefore, to investigate the changes in EMGpara 
induced by airway challenge testing, and to determine the relative independent 
contributions of bronchoconstriction and increased end-expiratory lung volume.  We 
hypothesised that EMGpara would increase in relation to the degree of 
bronchoconstriction, and that hyperinflation would exert a further influence on 
changes in EMGpara. 
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Methods 
Ethical approval for the study was granted by the King’s College Hospital Research 
Ethics Committee (reference number 09/H0808/100).  All subjects gave written 
informed consent for participation in the study.  All ethical aspects of the 
experiments conformed to the Declaration of Helsinki. 
 
Subjects 
Thirty two subjects with a self reported history of atopy, asthma or known bronchial 
hyperresponsiveness were studied.  The median (IQR) age of the group was 29.2 
(24.3 – 33.5) years.  All subjects had spirometry within normal limits at baseline. 
 
Anthropometry 
Height was measured using a wall-mounted stadiometer (Harpenden, Holtain Ltd, 
Crymych, UK) with a resolution of 1mm (range 600-1200 mm).  The subject was 
asked to remove footwear and stand upright with heels, back and occiput against 
the stadiometer.  A 1kg weight was placed on the stadiometer carriage to improve 
accuracy. 
 
Weight was measured using an electronic medical scale (HR Person Scale, Marsden 
Ltd, Henley on Thames, UK) with a resolution of 0.05kg and a maximum weighing 
capacity of 300kg.  The subject was asked to remove footwear and any heavy 
clothing and remain stationary on the scale until a steady reading was obtained. 
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Parasternal intercostal electromyography 
Skin was prepared in accordance with international guidelines for EMG recording 
(Hermans et al., 2000).  Initially the skin was scrubbed with an abrasive gel (Nuprep, 
Weaver and Company, Aurora, USA) to remove dead skin cells and excessive sebum 
in order to minimise electrode-skin impedance.  Any remaining gel and sebum was 
then removed with an alcohol-impregnated wipe before self-adhesive silver-silver-
chloride electrodes were applied (Kendall Arbo, Tyco Healthcare, Neustadt/Donau, 
Germany).  Electrodes were applied in the second intercostal space bilaterally, 3cm 
lateral to the sternum, with a reference electrode placed on the acromion process of 
the scapula. 
 
Signals were amplified and band-pass filtered between 10 and 3,000Hz, with an 
additional analogue notch filter at 50Hz to minimise mains frequency interference, 
using a PClab 3808 Biomedical Amplifier (Yinghui Medical Technology Co. Ltd, 
Guangzhou, China).  EMG signals were acquired (PowerLab 16SP, ADInstruments, 
Sydney, Australia) and displayed on a laptop computer (MacBook Pro, Apple, 
Cupertino, USA) running LabChart software (Version 7.2, ADInstruments Pty, 
Colorado Springs, USA) with analogue to digital sampling at 10kHz.  Both amplifier 
and analogue-to-digital convertor were earthed to suitable points in the laboratory.  
An additional 20Hz post-acquisition digital high-pass filter was applied via the 
LabChart software to assist in the removal of ECG artefact.  Data were displayed as 
both raw EMG and as a root mean square (RMS) trace, using a moving average 
window of 50ms (Ives & Wigglesworth, 2003).   
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EMGpara was recorded during tidal breathing.  Subjects were seated upright in a 
chair with back supported, arms placed on armrests and feet flat on the floor to 
minimise trunk postural activity.  Subjects were instructed to remain still and not to 
speak throughout the recording period.   
 
EMGpara activity, occurring between QRS complexes, was highlighted and the peak 
RMS EMGpara calculated.  The mean peak RMS EMGpara per breath was calculated 
over the final minute of each recording period. 
 
 
Spirometry 
Spirometry was performed in accordance with American Thoracic Society/European 
Respiratory Society (ATS/ERS) criteria (Miller et al., 2005) using a portable electronic 
spirometer (KoKo spirometer, Ferraris Respiratory, Louisville, CO, USA).  The correct 
technique was explained and demonstrated to each subject prior to testing.  The 
subject was seated upright with head and neck in a neutral or slightly extended 
position, fitted with a noseclip and asked to seal their lips tightly around a flanged 
mouthpiece.  The subject was then asked to inspire rapidly and fully to total lung 
capacity (TLC) and then, following a pause of no more than one second, to perform a 
maximal forceful exhalation and to maintain expiratory flow until no more air could 
be expelled.  Subjects were encouraged to “blast”, rather than “blow”, the air from 
the lungs, and strong verbal encouragement was given throughout each manoeuvre 
to promote complete exhalation.  Any traces showing evidence of incomplete 
exhalation, glottic closure, cough or air leak were rejected.  Repeated efforts were 
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performed at baseline until three acceptable manoeuvres were obtained.  
Acceptable repeatability was considered to have been obtained when the difference 
between the largest and second-largest values was less than 150ml or 5%.  Values 
for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) 
were expressed as a percentage of predicted values (Quanjer et al., 1993). 
 
Methacholine challenge testing 
The methacholine challenge test was performed in accordance with international 
guidelines (American Thoracic Society, 2000).  Testing was performed in a well-
ventilated room.  Subjects were seated in a chair suitable for EMG recording and 
baseline pulmonary function testing was performed as described. 
 
The methacholine challenge was performed using a dosimeter (KoKo USB digidoser, 
Ferraris Respiratory, Louisville, CO, USA) and nebuliser (DeVilbiss 646 characterised 
nebuliser, Ferraris Respiratory, Louisville, CO, USA) with a certified output of 1.134ml 
min-1.  Subjects were required to wear a nose clip and inhale and exhale through the 
mouthpiece at a maximum flow of 0.5L sec-1 imposed by a flow restrictor.  Use of a 
dosimeter and flow restrictor improve accuracy and repeatability of the dose 
delivered (American Thoracic Society, 2000).  Inspiratory and expiratory duration 
were also fixed at five seconds using auditory prompts.  Subjects were given verbal 
encouragement to maintain respiratory flow at the required rate and for a sufficient 
duration.   
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Measurement of respiratory flow and volume 
Respiratory flow was measured using a pneumotachograph (range 0-800L min-1, 
model 4813, Hans Rudolph Inc. Kansas City, USA), attached to a flanged mouthpiece 
with the subject wearing a noseclip.  Differential pressure across the 
pneumotachograph was measured using a pressure transducer (MP45-16, Validyne, 
Northridge, USA).  The signal from the transducer was amplified  (CD280, Validyne, 
Northridge, USA), and recorded and displayed alongside EMGpara by the acquisition 
software (LabChart) with analogue-to-digital  sampling of 100Hz (PowerLab 16SP).  
Volume was measured via digital integration of the flow signal using LabChart 
software. 
 
Inspiratory capacity (IC) was obtained by asking the subject to perform a slow 
maximal inhalation to TLC from functional residual capacity (FRC).  This was repeated 
three times, each effort interspersed with three to five tidal breaths, and the mean 
of the three efforts recorded.  Significant hyperinflation was defined as a decrease in 
IC of ≥300ml (Lougheed et al., 2006). 
 
 
Protocol 
All testing was performed on a single occasion.  Participants were requested to 
refrain from taking short-acting beta-2 agonists or antihistamine medication and 
from consuming products containing caffeine (coffee, tea, cola, chocolate) on the 
day of testing.  Subjects were familiarised with study instrumentation and the 
protocol explained in detail.  Anthropometric and demographic data were recorded 
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and baseline spirometry performed.  The five-breath dosimeter protocol was 
employed, with an initial diluent step using 0.9% saline followed by methacholine 
concentrations of 0.0625, 0.25, 1, 4, 8, 16 and 32 mg ml-1 (Acetyl-B-Methyl Choline, 
Nova Laboratories, Wigston, Leicestershire, UK).  Doses were delivered at five 
minute intervals.   At the beginning of testing, the diluent was administered via the 
digidoser and a single technically acceptable FEV1 manoeuvre performed at 30 and 
90 seconds following dose delivery and the lower of the two values used.  Following 
the second forced expiratory manoeuvre, three IC manoeuvres were performed and 
EMGpara was then recorded during tidal breathing for the remaining three minutes 
until delivery of the next dose.  The protocol was repeated, using increasing doses of 
methacholine, until the subject’s FEV1 had fallen by 20% or more from the post-
diluent value, or until the maximum methacholine dose had been delivered.  If a 20% 
or greater fall in FEV1 was elicited, the test was discontinued and 
bronchoconstriction reversed through the administration of 400µg salbutamol. 
 
PC20 is defined as the provocative concentration of methacholine inducing a 20% fall 
in FEV1, and was calculated using the formula: 
PC20 =  
Where: 
C1 = penultimate methacholine concentration 
C2 = final methacholine concentration 
R1 = percent fall from post-diluent stage in FEV1 after C1 
R2 = percent fall from post-diluent stage in FEV1 after C2 
anti log logC1+ logC2 − logC1( ) 20 − R1( )
R2 − R1
 
  
 
  
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Statistical analysis 
Differences in EMGpara, FEV1 and IC from baseline (measurements made post-
diluent step) to end of test (EOT) were assessed using Wilcoxon’s matched pairs test.  
Differences between the groups of subjects in whom significant hyperinflation was 
and was not observed were assessed using the Mann-Whitney test.  Linear mixed 
model (LMM) analysis was then used to analyse dose-wise changes in both FEV1 and 
EMGpara, and thereafter to determine the independent influences of changes in 
FEV1 and IC on change in EMGpara.  Models were also fitted to determine the 
trajectories of EMGpara between the hyperinflating and non-hyperinflating groups.  
LMM is an extension of multiple regression, allowing irregularly spaced serial data 
for individuals to be combined in a single linear regression model, providing 
estimates of both longitudinal individual changes and group patterns (West, 2009). 
 
Fixed effects in the model were methacholine dose and FEV1 when examining the 
entire cohort, with further models constructed incorporating IC both as a continuous 
variable and a binary term (change in IC greater or less than 300ml).  Random effect 
variables in all models comprised methacholine dose and an intercept term. 
 
Models were estimated using restricted maximum likelihood (REML), with all models 
centred on the diluent dose such that the intercept terms would be interpretable as 
the mean value of the dependent variable at commencement of testing, and slope 
would represent the change in the dependent variable per dose.  Model fit to dose 
as linear and quadratic functions was evaluated due to the quadrupling/doubling 
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dose protocol used and the known sigmoidal shape of the conventional FEV1 dose-
response curve (American Thoracic Society, 2000).  The selection of an appropriate 
covariance structure for the residuals and the validity of the quadratic versus linear 
functions of methacholine dose were assessed by likelihood ratio testing based on 
the -2 REML log-likelihood difference between the original and modified models 
(West, 2009). 
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Results 
Participant characteristics are shown in Table 1.  All 32 subjects underwent full 
methacholine challenge testing with measurements of spirometry and EMGpara.  A 
subset of 20 individuals had additional measurement of inspiratory capacity (termed 
“IC sub-group”). 
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 Entire cohort (n=32) IC sub-group (n=20) 
Age (years) 29.2 (24.3 – 33.5) 
29.0 
(25.1 – 34.1) 
Sex (male : female) 12 : 20 6 : 14 
Height (m) 1.70 (1.63 – 1.76) 
1.71 
(1.66 – 1.76) 
Weight (kg) 68.4 (59.9 – 77.8) 
68.4 
(63.1 – 77.6) 
BMI (kg m-2) 24.4 (21.8 – 25.2) 
24.1 
(21.5 – 25.0) 
Ethnicity (n (%)) 
White:  26 (81.3%) 
Black:  1 (3.1%) 
Asian:  4 (12.5%) 
Other:  1 (3.1%) 
White:  19 (95%) 
Black:  1 (5%) 
Baseline FEV1 (%predicted) 97.1 (88.9 – 102.2) 
96.9 
(86.3 – 106.9) 
 
Table 1  Characteristics of subjects undergoing methacholine challenge testing, with measurement of FEV1 and EMGpara only (entire cohort), 
and additional measurement of inspiratory capacity (IC sub-group) 
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Of the 32 participants, 25 exhibited a clinically significant response to methacholine, 
defined as a decrease of 20% or greater in FEV1.  The median (IQR) change in FEV1 
was 27.8 (35.6 – 22.7)% in the responder subset, and 7.2 (14.1 – 4.1)% in the non-
responder group.  All 20 of the subjects in the IC sub-group showed a clinically 
significant response, with a median (range) fall in FEV1 of 28.9 (37.0 – 22.8)%. 
 
Significant changes were observed from baseline to end of test (EOT) in FEV1 and 
EMGpara in both the entire cohort and the ‘responder’ subset.  The change in FEV1 
was significant in the non-responder group but not the change in EMGpara.  
Significant changes were observed in all parameters (FEV1, EMGpara and IC) in the IC 
sub-group of subjects.  These results are summarised in Figures 1, 2 and 3 and Table 
2.
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Table 2  Baseline to end-of-test changes in FEV1, EMGpara and IC in the full study 
cohort and subgroups. 
 
  Baseline End of test p value 
En
tir
e c
oh
or
t 
(n
=3
2)
 
FEV1 (% 
predicted) 
97.10 
(80.00 – 122.30) 
70.95 
(37.98 – 100.70) <0.0001 
EMGpara (µV) 5.02 (2.00 – 8.92) 
5.86 
(2.37 – 19.60) <0.0001 
Re
sp
on
de
rs 
(n
=2
5)
 
FEV1 (% 
predicted) 
96.00 
(80.00 – 122.30) 
67.80 
(37.98 – 92.27) <0.0001 
EMGpara (µV) 5.37 (2.25 – 8.92) 
6.27 
(3.37 – 19.60) <0.0001 
No
n-
re
sp
on
de
rs 
(n
=7
) 
FEV1 (% 
predicted) 
98.46 
(90.67 – 103.04) 
91.43 
(82.75 – 98.86) 0.028 
EMGpara (µV) 3.54 (3.15 – 3.91) 
4.59 
(4.35 – 5.88) 0.091 
IC
 m
ea
su
re
m
en
t  
    
   
su
b-
gr
ou
p 
(n
=2
0)
 FEV1 (% predicted) 
96.86 
(80.00 – 122.30) 
67.50 
(37.98 – 92.27) <0.0001 
EMGpara (µV) 5.37 (2.85 – 8.92) 
6.63 
(3.77 – 19.60) 0.0012 
IC (% 
predicted) 
91.9 
(65.6 – 133.3) 
84.9 
(39.8 – 129.0) 0.0037 
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LMM analysis demonstrated a significant positive interaction between a quadratic 
function for methacholine dose and change in EMGpara.  There was an additional 
effect of the change in FEV1 by dose on EMGpara, with the slope of the EMGpara 
versus dose2 line increasing by 0.002µV dose-2 (full cohort) or 0.003µV dose-2 (Part B 
cohort) for each percent of predicted decrease in FEV1.  See Table 3 for full details of 
slopes and intercepts of these interactions.  There was no significant effect of FEV1 
on the intercept of the EMGpara versus dose relationship, indicating no significant 
influence of baseline FEV1 on pre-challenge EMGpara.  Figure 4 shows the LMM-
predicted EMGpara values plotted against measured FEV1. 
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Table 3  Linear mixed models for covariates in the full study cohort and those undergoing measurement of IC.  Intercepts are in µV, slopes in 
µV per dose number2 (as dose was treated as a quadratic function).
 Covariate Coefficient (95% CI) p value 
Entire cohort (n=32) Dose number2 
For intercept:  4.09 (0.61 – 7.57) 
 
For slope:  0.24 (0.11 – 0.37) 
0.22 
 
<0.001 
 FEV1 
For intercept:  0.01 (-0.03 – 0.04) 
 
For slope:  -0.002 (-0.004 – -0.001) 
0.689 
 
0.01 
IC sub-group (n=20) Dose number2 
For intercept:  4.21 (0.34 – 8.07) 
 
For slope:  0.27 (0.12 – 0.42) 
0.033 
 
0.001 
 FEV1 
For intercept: 0.01 (-0.03 – 0.05) 
 
For slope:  -0.003 (-0.005 – -0.001) 
0.537 
 
0.011 
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Of the 20 participants undergoing measurement of IC, 10 demonstrated significant 
hyperinflation, defined as a decrease in inspiratory capacity of greater than or equal 
to 300ml (Lougheed et al., 2006).  There were no differences in the characteristics of 
the subjects in the hyperinflating (HI) and non-hyperinflating (NH) groups, nor were 
there differences in the degree of bronchoconstriction or change in EMGpara at EOT 
between the HI and NH groups (Table 4).   
 
 
 
 Hyperinflating      
group (n=10) 
Non-hyperinflating 
group (n=10) p value 
ΔFEV1 (%) -32.5 (-36.2 – -27.5) 
-23.3 
(-38.3 – -22.5) 0.22 
ΔEMGpara (%) 25.3 (-4.6 – 95.8) 
40.1 
(1.2 – 101.1) 0.78 
 
Table 4  Relative percentage changes in FEV1 and EMGpara in the subjects 
demonstrating a reduction in inspiratory capacity of ≥300ml (hyperinflating group) 
and those showing a change in IC of <300ml (non-hyperinflating group).  
 
 
Inspection of the residuals from the models diagnostics derived from LMM analysis 
showed that the IC data did not satisfy the assumption of homoscedasticity.  The 
model was therefore reassessed following logarithmic transformation of the IC 
values.  LMM analysis did not demonstrate a significant effect of the change in IC by 
dose on change in EMGpara, either when treated as a continuous variable (Table 5) 
or as a binary outcome (change in IC of greater than or less than 300ml). 
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Covariate Coefficient (95% CI) p value 
Dose number2 
For intercept:  4.19 (-7.71 – 16.09) 
 
For slope:  0.01 (-0.74 – 0.77) 
0.477 
 
0.972 
FEV1 
For intercept:  0.01 (-0.03 – 0.06) 
 
For slope:  -0.003 (-0.005 – -0.001) 
0.578 
 
0.006 
logIC 
For intercept:  0.02 (-2.62 – 2.66) 
 
For slope:  0.07 (-0.10 – 0.24) 
0.988 
 
0.438 
 
Table 5 Linear mixed models for covariates in Part B.  Intercepts are in µV, slopes in µV per dose number2 (as dose was treated as a quadratic 
function).  Values for the influence of dose2 and FEV1 on EMGpara are different to those displayed in Table 2 due to the incorporation of 
additional data into the model.
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Discussion 
This study has investigated in detail respiratory load compensation using the changes 
in parasternal intercostal muscle activity during chemical airway challenge, and has 
allowed the investigation of the interaction between decrements in key pulmonary 
function parameters and change in respiratory muscle activity.  The hypothesis that 
EMGpara would increase in proportion with decrements in FEV1 was supported; the 
secondary hypothesis, that hyperinflation would independently result in further 
increases in EMGpara, was refuted.  These data suggest that during airway challenge 
testing bronchoconstriction imposes a greater relative load on the respiratory 
system as indicated by increased neural drive to the parasternal intercostal muscles 
than concomitant changes in end expiratory lung volume. 
 
Maarsingh et al. (2002) examined the relationship between FEV1 and respiratory 
muscle activity assessed using both parasternal intercostal and surface diaphragm 
EMG during histamine-induced bronchoconstriction in 15 asthmatic children.  As 
with the current study, they observed a good agreement between the degree of 
airway narrowing and increases in EMG activity.  Unlike the current study, however, 
the EMG data were expressed as the logarithm of the ratio of the EMG activity at 
each stage to that at baseline.  This linear increase in the log transformed EMG data 
suggests that EMG activity in their study increased exponentially.  Close agreement 
was also observed between the increase in EMG activity and decreases in FEV1 
expressed in 5% decrements from baseline, determined by linear interpolation.  
Expressing the data in this way however, risks biasing the results towards a 
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relationship.  The linear mixed effects modelling used in the current study represents 
a more robust method for analysing data of this nature. 
 
Lavorini et al. (2013) also observed significant increases in EMGpara between 
baseline and EOT during methacholine-induced bronchoconstriction in 44 adults 
with mild asthma.  No specific analysis was undertaken, however, of the 
relationships between airways obstruction (measured using the respiratory 
interrupter technique) and EMGpara.  
 
Surface EMG of the second intercostal space can detect activity in nearby muscles, 
and close attention to subjects’ posture and upper limb movements is essential.  
Nearby large accessory muscles such as pectoralis major are, however, not normally 
recruited during tidal breathing.  Postural influences on EMGpara activity have been 
reported (Hudson et al., 2010) and we therefore ensured that subjects were well 
supported in the seated position to eliminate any contribution from postural activity.  
Subjects were also encouraged to refrain from any upper limb movements during 
recording periods, and EMG traces were carefully inspected to ensure absence of 
artefact.  The EMGpara technique applied within the current study has previously 
been demonstrated to be reproducible (Reilly et al., 2011) and to agree with values 
obtained simultaneously using needle electrodes (Silver & Lehr, 1981).  International 
guidelines state surface respiratory EMG techniques to be of benefit in assessing 
response to altered respiratory load, and to reflect changing neural output to the 
respiratory muscles (American Thoracic Society & European Respiratory Society, 
2002). 
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Although airway challenge testing does not completely mirror the acute or 
progressive chronic pathophysiological changes that occur in obstructive lung 
disease, methacholine challenge testing is thought to reproduce the adverse 
mechanical consequences of a moderately severe asthma exacerbation (Pride & 
Macklem, 2011) and therefore represents a suitable model for the interpretation of 
changes in pulmonary function likely to be seen in asthmatic patients.  Some studies 
examining end-expiratory lung volume changes during acute asthma exacerbations 
have, however, demonstrated somewhat greater hyperinflation (mean IC values 
approximately 50% lower) than was observed in the current study (Pretto et al., 
2007; Azevedo et al., 2012) and thus the potential for heterogeneity in the 
pathophysiological changes between these different study settings must be 
recognised.  Further exploration of the influence of hyperinflation and airflow 
obstruction within clinical populations would be of interest. 
 
This is the first study to examine the independent relative contributions of airway 
obstruction and hyperinflation to respiratory load and NRD. Previous cross-sectional 
studies have demonstrated relationships between the severity of airflow obstruction 
(as quantified by FEV1), measures of end-expiratory lung volume and levels of NRD 
measured using EMGdi  (Jolley et al., 2009) and/or EMGpara (Reilly et al., 2011)).  
These studies did not perform multivariate analyses to investigate the independent 
influence of each factor.  In the current study, no effect of FEV1 on the intercept of 
EMGpara was observed, suggesting no relationship between baseline levels of 
airway obstruction and NRD.  This is not, however, surprising, given the narrow 
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range of FEV1 values at baseline, all of which fell within normal limits.  Other studies 
examining longitudinal changes in pulmonary function and EMGpara during acute 
exacerbations of lung disease (Murphy et al., 2011; Reilly et al., 2012) have the 
additional confounding influence of the metabolic load of acute illness and infection, 
making interpretation of relationships more challenging.  These previous data show 
markedly larger changes in EMGpara than seen in the current study, though the 
populations under investigation are substantially different.  It is plausible that the 
relationship between airflow obstruction is curvilinear, and future studies could 
consider examining larger cohorts to allow detailed cross-sectional or longitudinal 
measurements to be made across the full spectrum of disease severity. 
 
LMM analysis did not demonstrate a significant effect of changing IC on change in 
EMGpara, suggesting little contribution of lung hyperinflation to overall respiratory 
load.  The known influence of increased lung volume on the length-tension 
characteristics of the respiratory muscles would suggest that it is likely that 
hyperinflation would have an influence on levels of NRD, and indeed previous 
studies have demonstrated relationships between measures of end-expiratory lung 
volume and NRD (Jolley et al., 2009; Reilly et al., 2011).  The severity of 
hyperinflation reported in these studies was, however, much more pronounced 
(lowest IC values of approximately 44% predicted and 1.1L respectively) than that 
observed in the present study, in which the median reduction in IC was only 245ml, 
with all participants having normal lung function at baseline.  Such modest changes 
in end expiratory in lung volume in the current study would most likely have resulted 
in pulmonary mechanics remaining within the linear portion of the respiratory 
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system compliance curve, thus markedly greater levels of NRD and transpulmonary 
pressures would not have been required to achieve equivalent levels of tidal 
breathing.  The parasternal intercostal muscles, while known to act in concert with 
the diaphragm (De Troyer & Estenne, 1984) and respond similarly in regard to 
alterations in the respiratory load-capacity balance, do not show an identical 
activation pattern (Reilly et al., 2011).  Specifically, they experience less of a 
decrement in their mechanical advantage with increasing lung volume than does the 
diaphragm (Decramer & De Troyer, 1984).  Conversely, increases in operating lung 
volumes can have a beneficial effect under conditions of mild airflow obstruction, by 
increasing radial traction on the airways, increasing airway calibre (Briscoe & Dubois, 
1958) and reducing airway resistance.  These factors may combine to explain the lack 
of influence of changes in IC on EMGpara in the current study.  It must also be 
recognised that the number of subjects within the current study somewhat limits the 
statistical power to interpret the relatively modest changes in lung volume elicited 
by the challenge test when incorporating multiple terms into the linear mixed model. 
 
In conclusion, we have demonstrated methacholine-induced increases in neural 
drive to the parasternal intercostal muscles in adult subjects, the degree of which 
was influenced by the magnitude of airflow obstruction.  Moderate changes in end-
expiratory lung volume did not in this study influence levels of parasternal 
intercostal EMG activity.   
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Figure legends 
Figure 1  Baseline to end-of-test (EOT) changes in FEV1 in 32 subjects undergoing 
methacholine challenge testing.  Subjects undergoing measurement of IC (n=20) are 
indicated by filled circles, responders without IC measurements in open circles (n=5) 
and non-responders (n=7) by open squares. 
 
Figure 2  Baseline to end-of-test (EOT) changes in EMGpara in 32 subjects 
undergoing methacholine challenge testing.  Subjects undergoing measurement of IC 
(n=20) are indicated by filled circles, responders without IC measurements in open 
circles (n=5) and non-responders (n=7) by open squares. 
 
Figure 3  Baseline to end-of-test changes in inspiratory capacity in 20 subjects 
undergoing IC measurements during methacholine challenge testing. 
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Figure 4  Individual subjects’ trajectories (n=32) of predicted EMGpara data based on 
linear mixed model analysis, plotted against measured FEV1 change from baseline. 
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